Compounds and method for treatment of cancer

1. A method for treating a cancer in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of Formula I or IA:

a pharmaceutically-acceptable salt, tautomer, optical isomer, and/or combination thereof;

wherein:

R 1 and R 2 together form a substituted or unsubstituted polycyclic ring comprising at least two ring systems, said at least two ring systems comprising a first ring system bonded to C1 and a second ring system fused to the first ring system, wherein:

the first ring system is a substituted or unsubstituted aromatic group, the second ring system is a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted carbocyclic group, or a substituted or unsubstituted heterocyclic group; or

the first ring system is a substituted or unsubstituted heteroaromatic group, the second ring system is a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted carbocyclic group, or a substituted or unsubstituted heterocyclic group; or

the first ring system is a substituted or unsubstituted saturated carbocyclic group, the second ring system is a substituted or unsubstituted aromatic group, a substituted or unsubstituted unsaturated carbocyclic group, a substituted or unsubstituted heterocyclic group, or a substituted or unsubstituted ring B:

wherein X 1 to X 6 are each independently selected from carbon or a heteroatom; or

the first ring system is a substituted or unsubstituted unsaturated carbocyclic group, the second ring system is a substituted or unsubstituted aromatic group, a substituted or unsubstituted carbocyclic group, a substituted or unsubstituted heterocyclic group, or a substituted or unsubstituted ring B:

wherein X 1 to X 6 are each independently selected from carbon or a heteroatom; or

the first ring system is a substituted or unsubstituted heterocyclic group, the second ring system is a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted carbocyclic group, or a substituted or unsubstituted heterocyclic group; and

R 3 to R 11 are each independently selected from H, a substituted or unsubstituted hydrocarbon group, a substituted or unsubstituted heterogeneous group, a substituted or unsubstituted carbocyclic group, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aromatic, or a substituted or unsubstituted heteroaromatic;

R 12 is selected from H or a hydrocarbyl group;

Y is N;

Ring is selected from a substituted or unsubstituted thiomorpholinyl group, a substituted or unsubstituted morpholinyl group, or a substituted or unsubstituted piperidinyl group, wherein the nitrogen in the Ring is bonded to A; and

n is 0 or 1,

when n is 1, A is a substituted or unsubstituted heteroaromatic,

wherein the cancer is selected from small cell lung cancer, non-small cell lung cancer, breast cancer, acute leukemia, chronic leukemia, colorectal cancer, or brain cancer.

2. The method according to claim 1 , wherein the first ring system is a substituted or unsubstituted heterocyclic group, the second ring system is a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted carbocyclic group, or a substituted or unsubstituted heterocyclic group.

3. The method according to claim 1 , wherein the first ring system is a substituted or unsubstituted unsaturated carbocyclic group, the second ring system is a substituted or unsubstituted aromatic group, a substituted or unsubstituted carbocyclic group, a substituted or unsubstituted heterocyclic group; or a substituted or unsubstituted ring B:

wherein X 1 to X 6 are each independently selected from carbon or a heteroatom.

4. The method according to claim 1 , wherein the first ring system is a substituted or unsubstituted carbocyclic group and the second ring system is a substituted or unsubstituted ring B:

wherein X 1 to X 6 are each independently selected from carbon or a heteroatom.

5. The method according to claim 3 , wherein X 1 is N and X 2 to X 6 is carbon.

6. The method according to claim 4 , wherein X 1 is N and X 2 to X 6 is carbon.

7. The method according to claim 5 , wherein the ring B is fused to the first ring system at X 2 and X 3 .

8. The method according to claim 6 , wherein the ring B is fused to the first ring system at X 2 and X 3 .

9. The method according to claim 1 , wherein the first ring is a five-membered ring.

10. The method according to claim 1 , wherein the first ring is a six-membered ring.

11. The method according to claim 1 , wherein the substituted or unsubstituted polycyclic ring further comprises a third ring system fused to the first ring system.

12. The method according to claim 11 , wherein the third ring system is a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted carbocyclic group, or a substituted or unsubstituted heterocyclic group.

13. The method according to claim 12 , wherein the third ring system is a substituted or unsubstituted heteroaromatic group or a substituted or unsubstituted heterocyclic group.

14. The method according to claim 1 , wherein n is 0.

15. The method according to claim 1 , wherein n is 1.

16. The method according to claim 15 , wherein A is a pyridinyl group.

17. The method according to claim 1 , the compound is Formula I and Y is N.

18. The method according to claim 17 , wherein R 7 is a substituted or unsubstituted alkyl group or a substituted or unsubstituted heteroaromatic group and R 3 to R 6 and R 8 to R 12 are each independently selected from H or a substituted or unsubstituted hydrocarbon group.

19. The method according to claim 17 , wherein R 7 is the substituted or unsubstituted alkyl group or a substituted or unsubstituted pyridyl group and R 3 to R 6 and R 8 to R 12 are each H.

20. The method according to claim 1 , wherein the compound penetrates the blood brain barrier of a mammal.

21. The method according to claim 1 , wherein at least about 50% of the compound is orally absorbed by a mammal.

22. The method according to claim 1 , wherein the compound has an IC 50 for a cancer cell population of less than about 1000 nM.

23. The method according to claim 1 , wherein the compound is co-administered with radiation therapy.

24. The method according to claim 1 , wherein the mammal is a human.

25. The method according to claim 1 , wherein the compound inhibits development of a drug resistant form of the cancer.

26. The method according to claim 1 , wherein the cancer is a carcinoma.

27. The method according to claim 26 , wherein the carcinoma is selected from small cell lung carcinomas, breast carcinomas, or colorectal carcinomas.

28. The method according to claim 27 , wherein the carcinoma is small cell lung carcinoma.

29. The method according to claim 1 , wherein the compound is administered orally and/or parenterally.